CPAP fails to improve glycemic control or variability in diabetes patients with sleep apnea
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-04-20 05:45 GMT | Update On 2023-04-20 10:57 GMT
USA: Positive airway pressure (PAP) fails to improve glycemic control or variability among patients with moderate-to-severe OSA (obstructive sleep apnea) and type 2 diabetes, a recent study has pointed out. The findings appeared in the CHEST journal on April 13, 2023.Exploratory analyses revealed that in women, PAP therapy may improve glucose variability. Bedtime and post-dinner glucose...
Login or Register to read the full article
USA: Positive airway pressure (PAP) fails to improve glycemic control or variability among patients with moderate-to-severe OSA (obstructive sleep apnea) and type 2 diabetes, a recent study has pointed out. The findings appeared in the CHEST journal on April 13, 2023.
Exploratory analyses revealed that in women, PAP therapy may improve glucose variability. Bedtime and post-dinner glucose levels were higher in those who did not receive PAP therapy.
Glycemic variability is linked with an increased risk for CVD (cardiovascular disease) in type 2 diabetes patients independent of HbA1c (glycosylated haemoglobin) levels. Given the conflicting evidence on the effect of PAP therapy for obstructive sleep apnea on HbA1c, exploring its impact on glycemic variability is valuable.
R. Nisha Aurora, NYU Grossman School, New York City, NY, USA, and colleagues determined if using PAP therapy for OSA improves glycemic variability in type 2 diabetes patients in a randomized controlled trial.
The trial involved 184 patients with type 2 diabetes and moderate-to-severe OSA. Participants received either three months of PAP therapy with lifestyle counselling or lifestyle counselling alone. Endpoints included standard deviation of glucose levels and other metrics derived from CGM (continuous glucose monitoring) and self-monitoring of blood glucose.
The study led to the following findings:
· No differences between the two groups were noted in either primary or secondary CGM endpoints.
· Average PAP therapy use was 5.4 hours per night (SD: 1.6).
· Exploratory analyses by sex showed remarkable differences in the primary and secondary outcomes.
· PAP therapy in women was linked with improvement in the standard deviation of glucose levels, with 3.5 mg/dl being the mean difference of change between intervention and control groups.
· PAP therapy was also linked with lower post-dinner and bedtime glucose levels: 20.1 mg/dl and 34.6 mg/dl, respectively.
"In patients with moderate-to-severe obstructive sleep apnea and type 2 diabetes, PAP therapy did not improve glycemic control or variability," the researchers concluded.
Reference:
Aurora, R Nisha, et al. "Effects of Positive Airway Pressure Therapy On Glycemic Variability in Patients With Type 2 Diabetes and Obstructive Sleep Apnea: a Randomized Controlled Trial." Chest, 2023.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd